Decision guide
Bariatric surgery vs GLP-1 medications
The two highest-efficacy interventions for severe obesity. They are not equivalent. Surgery offers more durable loss; GLP-1s offer reversibility and a lower entry barrier. Most patients now start with GLP-1s and consider surgery if response is inadequate.
Head-to-head
| Factor | Bariatric surgery | GLP-1 medications |
|---|---|---|
| Avg total weight loss | Sleeve: 25-30% · Bypass: 30-35% | Wegovy: 15% · Zepbound: 21% |
| Durability without intervention | Mostly maintained at 10 years (60-70%) | ~2/3 regain within 1 year of discontinuation |
| Total cost | $15,000-25,000 one-time (often insured) | $5,000-15,000+/year ongoing |
| Recovery time | 2-6 weeks post-op | None — start at home |
| Risk of major complications | Mortality <0.3%; complication rate 5-15% | <1% serious AE (pancreatitis, gallbladder) |
| Diabetes remission rate | 50-70% (Roux-en-Y) | A1C reduction 1-2.4%; rarely full remission |
| Reversibility | Sleeve: irreversible · Bypass: technically reversible, rare | Fully reversible — stop and effects fade |
When obesity-medicine specialists choose surgery
Most US guidelines support surgery at BMI ≥40, or BMI ≥35 with at least one severe obesity-related comorbidity (T2D, OSA, joint disease, heart failure). Surgery is often considered first when weight loss must be substantial and durable within 12-18 months — commonly to qualify for organ transplant, joint replacement, or fertility treatment.
When GLP-1s are the better starting point
Patients at BMI 30-40 without severe comorbidities typically start with GLP-1s. Lower procedural risk, reversibility, and the ability to titrate or pause make the medication path the default for most patients in obesity-medicine practice today.